Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
News Pfizer fears rough ride with NICE over breast cancer drug Concerns over NICE's treatment of add-on therapies.
News Pfizer looks to confirm US licence for breast cancer pill Pfizer has filed late stage data with FDA.
News Women urged to look for "non-lump" breast cancer symptoms Patients with "non lump" symptoms more likely to delay doctor visit.
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News Novartis' LEE011 on fast track to challenge Ibrance US regulator grants fast review for breast cancer drug.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
